Floatz logo

Tazemetostat

Indolent B-cell Lymphoma

Shanghai YingLi Pharmaceutical Co. Ltd.Small moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Indolent B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Linperlisib
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 4BB
Velpatasvir
Fondazione Italiana Linfomi - ETS
Phase 2B
Ledipasvir
Fondazione Italiana Linfomi - ETS
Phase 2B
Sofosbuvir
Fondazione Italiana Linfomi - ETS
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Massachusetts General Hospital
Phase 2B
Di-B4
Cancer Research UK
Phase 1CC
Tetrahydrouridine
Yogen Saunthararajah
Early Phase 1CC
Decitabine
Yogen Saunthararajah
Early Phase 1CC

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →